Showing papers by "Jacoline E C Bromberg published in 2023"
TL;DR: Bromberg et al. as mentioned in this paper discussed the future of maintenance temozolomide chemotherapy in PCNSL. But, they did not consider the effect of the treatment on the patient.
Abstract: Journal Article Is there a future for maintenance temozolomide chemotherapy in PCNSL? Get access Jacoline E C Bromberg, Jacoline E C Bromberg Department of Neuro-Oncology, Erasmus MC University Medical Center Cancer Institute, Rotterdam, the Netherlands Corresponding Author: Jacoline E. C. Bromberg, MD, Department of Neuro-Oncology, Erasmus MC Cancer Institute, PO Box 2040, 3000 CA Rotterdam, The Netherlands (j.bromberg@erasmusmc.nl) Search for other works by this author on: Oxford Academic PubMed Google Scholar Jeanette K Doorduijn Jeanette K Doorduijn Department of Hematology, Erasmus MC University Medical Center Cancer Institute, Rotterdam, The Netherlands Search for other works by this author on: Oxford Academic PubMed Google Scholar Neuro-Oncology, Volume 25, Issue 4, April 2023, Pages 699–700, https://doi.org/10.1093/neuonc/noad015 Published: 19 January 2023 Article history Published: 19 January 2023 Corrected and typeset: 13 February 2023
TL;DR: In this paper , the authors evaluated the toxicity and efficacy of the Dutch treatment protocol for adult medulloblastoma patients, which is a rare tumor in adults, based on residual disease, histological subtype and extent of disease.
Abstract: Medulloblastoma is a rare tumor in adults. The objective of this nationwide, multicenter study was to evaluate the toxicity and efficacy of the Dutch treatment protocol for adult medulloblastoma patients.Adult medulloblastoma patients diagnosed between 2010 and 2018 were identified in the Dutch rare tumors registry or nationwide pathology database. Patients with intention to treat according to the national treatment protocol were included. Risk stratification was performed based on residual disease, histological subtype and extent of disease. All patients received postoperative radiotherapy [craniospinal axis 36 Gy/fossa posterior boost 19.8 Gy (14.4 Gy in case of metastases)]. High-risk patients received additional neoadjuvant (carboplatin-etoposide), concomitant (vincristine) and adjuvant chemotherapy (carboplatin-vincristine-cyclophosphamide) as far as feasible by toxicity. Methylation profiling, and additional next-generation sequencing in case of SHH-activated medulloblastomas, were performed.Forty-seven medulloblastoma patients were identified, of whom 32 were treated according to the protocol. Clinical information and tumor material was available for 28 and 20 patients, respectively. The histological variants were mainly classic (43%) and desmoplastic medulloblastoma (36%). Sixteen patients (57%) were considered standard-risk and 60% were SHH-activated medulloblastomas. Considerable treatment reductions and delays in treatment occurred due to especially hematological and neurotoxicity. Only one high-risk patient could complete all chemotherapy courses. 5-years progression-free survival (PFS) and overall survival (OS) for standard-risk patients appeared worse than for high-risk patients (PFS 69% vs. 90%, OS 81% vs. 90% respectively), although this wasn't statistically significant.Combined chemo-radiotherapy is a toxic regimen for adult medulloblastoma patients that may result in improved survival.